Mepenex (Meropenem Anhydrous)

Meropenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, blocking the final cross‑linking step of peptidoglycan formation. This leads to loss of cell‑wall integrity and bactericidal death of susceptible Gram‑positive, Gram‑negative and anaerobic organisms.

The dosage of Mepenex is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function and other clinical factors. Healthcare professionals determine the appropriate infusion rate and duration.

The safety of meropenem in pregnancy and lactation is not well established. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after careful consideration by the treating physician.

To request Mepenex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and any required import documentation.

Meropenem offers a broad spectrum of activity similar to other carbapenems such as imipenem‑cilastatin, but it is more stable against many beta‑lactamases and does not require co‑administration of a renal protective agent. Its dosing flexibility and lower risk of certain toxicities make it a preferred option in many severe infections.

Mepenex should be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution. Do not use if the product has been exposed to temperatures outside this range.

Mepenex is supplied as a sterile injection solution for intravenous infusion. It is administered by a healthcare professional through a peripheral or central venous line, typically over a period of 15‑30 minutes, according to the dose prescribed by the clinician.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant changes in blood counts or renal function. Prompt medical attention is required if these occur.

Mepenex is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any beta‑lactam antibiotics. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving interacting medications without appropriate monitoring.